Patents by Inventor Jim E. Cutler
Jim E. Cutler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9416173Abstract: Several new peptides have been developed that show effectiveness as vaccines against candidiasis and other fungal diseases. A new conjugate vaccine of a ?-mannotriose linked to a fungal peptide linked to tetanus toxin has been shown to be effective as a vaccine with or without use of an adjuvant. In addition, a monoclonal antibody has been identified that offers protection from a Candida infection.Type: GrantFiled: April 20, 2012Date of Patent: August 16, 2016Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical CollegeInventors: Hong Xin, Jim E. Cutler
-
Publication number: 20140037641Abstract: Several new peptides have been developed that show effectiveness as vaccines against candidiasis and other fungal diseases. A new conjugate vaccine of a ?-mannotriose linked to a fungal peptide linked to tetanus toxin has been shown to be effective as a vaccine with or without use of an adjuvant. In addition, a monoclonal antibody has been identified that offers protection from a Candida infection.Type: ApplicationFiled: April 20, 2012Publication date: February 6, 2014Applicant: LSU Systems OfficeInventors: Jim E. Cutler, Hong Xin, David R. Bundle, Sebastian Dziadek
-
Publication number: 20100209448Abstract: The present invention provides methods of making and using immunogenic oligosaccharide compositions comprising native O-linked and S-linked oligosaccharides coupled to a protein carrier, wherein the resultant conjugate elicits a protectively immunogenic response. These compositions may be useful in vaccines against pathogenic Candida species.Type: ApplicationFiled: March 30, 2010Publication date: August 19, 2010Inventors: David R. Bundle, Mark Nitz, Jim E. Cutler
-
Patent number: 7722890Abstract: The present invention provides methods of making and using immunogenic oligosaccharide compositions comprising native O-linked and S-linked oligosaccharides coupled to a protein carrier, wherein the resultant conjugate elicits a protectively immunogenic response. These compositions may be useful in vaccines against pathogenic Candida species.Type: GrantFiled: April 25, 2003Date of Patent: May 25, 2010Assignee: Theracarb, Inc.Inventors: David R. Bundle, Mark Nitz, Jim E. Cutler
-
Publication number: 20080233181Abstract: The present invention relates to nanoparticle vaccine adjuvants comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed on the carrier. Such antigen-displaying nanoparticles may also display a targeting molecule on its surface in order to direct it to a specific site or cell type to optimize a desired immune response. The present invention also relates to encapsulating an antigen or combinations of different antigens within such nanoparticles, with or without a targeting molecule displayed on its surface. The antigens used in this invention are effective to produce an immune response against a variety of pathological conditions.Type: ApplicationFiled: October 19, 2007Publication date: September 25, 2008Inventors: Jon O. Nagy, Benfang Lei, Zengshe Kevin Liu, Robert F. Bargatze, John W. Jutila, Jim E. Cutler, Pati M. Glee
-
Patent number: 7285289Abstract: The present invention relates to nanoparticle vaccines comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed on the carrier. Such antigen-displaying nanoparticles may also display a targeting molecule on its surface in order to direct it to a specific site or cell type to optimize a desired immune response. The present invention also relates to encapsulating an antigen or combinations of different antigens within such nanoparticles, with or without a targeting molecule displayed on its surface. The antigens used in this invention are effective to produce an immune response against a variety of pathological conditions.Type: GrantFiled: April 14, 2003Date of Patent: October 23, 2007Inventors: Jon O. Nagy, Robert F. Bargatze, John W. Jutila, Jim E. Cutler, Pati M. Glee
-
Publication number: 20040022840Abstract: The present invention relates to nanoparticle vaccines comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed on the carrier. Such antigen-displaying nanoparticles may also display a targeting molecule on its surface in order to direct it to a specific site or cell type to optimize a desired immune response. The present invention also relates to encapsulating an antigen or combinations of different antigens within such nanoparticles, with or without a targeting molecule displayed on its surface. The antigens used in this invention are effective to produce an immune response against a variety of pathological conditions.Type: ApplicationFiled: April 14, 2003Publication date: February 5, 2004Inventors: Jon O. Nagy, Robert F. Bargatze, John W. Jutila, Jim E. Cutler, Pati M. Glee
-
Publication number: 20030223938Abstract: The present invention relates to nanoparticles comprised of a carrier, particularly polymerized lipids, and ligands displayed on the carrier, wherein the ligands form a polyvalent binding unit that is effective to produce a specific interaction between the nanoparticle and receptors on a target, particularly under physiologically relevant shear conditions.Type: ApplicationFiled: April 14, 2003Publication date: December 4, 2003Inventors: John O. Nagy, Robert F. Bargatze, John W. Jutila, Jim E. Cutler, Yongmoon Han, Pati M. Glee, David Pascual
-
Patent number: 6630146Abstract: A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to infection by C. albicans. The composition includes phosphomannan of C. albicans. Monoclonal antibodies for use in passive immunization against candidal infections.Type: GrantFiled: December 11, 2000Date of Patent: October 7, 2003Assignee: Montana State UniversityInventors: Jim E. Cutler, Yongmoon Han
-
Publication number: 20030072775Abstract: A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to infection by C. albicans. The composition includes phosphomannan of C. albicans, peptide mimotopes of phosphomannan epitopes, or polynucleotides encoding the peptide mimotopes. Monoclonal antibodies for use in passive immunization against candida infections are also provided.Type: ApplicationFiled: February 14, 2002Publication date: April 17, 2003Applicant: The Research and Development Institute Inc.Inventors: Jim E. Cutler, Yongmoon Han, Pati M. Glee, Bruce L. Granger
-
Patent number: 6488929Abstract: A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to the infection by C. albicans. The composition includes phosphomannan of C. albicans. Monoclonal antibodies for use in passive immunization against candidal infections.Type: GrantFiled: July 12, 1999Date of Patent: December 3, 2002Assignee: Montana State UniversityInventors: Jim E. Cutler, Yongmoon Han
-
Publication number: 20020160009Abstract: A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to infection by C. albicans. The composition includes phosphomannan of C. albicans. Monoclonal antibodies for use in passive immunization against candidal infections.Type: ApplicationFiled: July 12, 1999Publication date: October 31, 2002Applicant: MORGAN, LEWIS AND BOCKUIS LLPInventors: JIM E. CUTLER, YONGMOON HAN
-
Patent number: 6403090Abstract: A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to infection by C. albicans. The composition includes phosphomannan of C. albicans, peptide mimotopes of phosphomannan epitopes, or polynucleotides encoding the peptide mimotopes. Monoclonal antibodies for use in passive immunization against candida infections are also provided.Type: GrantFiled: June 17, 1999Date of Patent: June 11, 2002Assignee: The Research and Development Institute Inc.Inventors: Jim E. Cutler, Yongmoon Han
-
Patent number: 6391587Abstract: A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to infection by C. albicans. The composition includes phosphomannan of C. albicans, peptide mimotopes of phosphomannan epitopes, or polynucleotides encoding the peptide mimotopes. Monoclonal antibodies for use in passive immunization against candida infections are also provided.Type: GrantFiled: June 17, 1999Date of Patent: May 21, 2002Inventors: Jim E. Cutler, Pati M. Glee, Bruce L. Granger
-
Publication number: 20020054886Abstract: A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to infection by C. albicans. The composition includes phosphomannan of C. albicans. Monoclonal antibodies for use in passive immunization against candidal infections.Type: ApplicationFiled: December 11, 2000Publication date: May 9, 2002Applicant: The Research and Development Institute Inc.Inventors: Jim E. Cutler, Yongmoon Han
-
Patent number: 6309642Abstract: A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to infection by C. albicans. The composition includes phosphomannan of C. albicans, peptide mimotopes of phosphomannan epitopes, or polynucleotides encoding the peptide mimotopes. Monoclonal antibodies for use in passive immunization against candida infections are also provided.Type: GrantFiled: May 13, 1998Date of Patent: October 30, 2001Assignee: The Research and Development Institute, Inc.Inventors: Jim E. Cutler, Pati M. Glee
-
Patent number: 5885791Abstract: An assay and test kit for testing and quantifying fungal inhibition by an antifungal agent. In the assay, inhibition is measured by a reduction in substrate uptake (such as glucose) as compared to uninhibited controls. A minimum inhibitory concentration value for each antifungal agent is obtained from the assay.Type: GrantFiled: November 16, 1995Date of Patent: March 23, 1999Assignees: The Research and Development Institute, Inc., The University of Virginia Patent FoundationInventors: Jim E. Cutler, Marcia H. Riesselman, Kevin C. Hazen
-
Patent number: 5578309Abstract: A composition, pharamaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to infection by C. albicans. The composition includes phosphomannoprotein which contains adhesins from C. albicans.Type: GrantFiled: June 7, 1995Date of Patent: November 26, 1996Assignee: The Research and Development Institute, Inc.Inventors: Jim E. Cutler, Yongmoon Han